Vilon (Lys-Glu, also designated KE dipeptide) is the shortest biologically active peptide in the Khavinson bioregulator series, consisting of just two amino acids — lysine and glutamic acid. Developed at the Saint Petersburg Institute of Bioregulation and Gerontology under the direction of Professor Vladimir Khavinson, Vilon was designed to mimic the biological activity of thymulin (facteur thymique sérique, FTS), the zinc-dependent nonapeptide hormone produced by thymic epithelial cells.

Overview

Vilon occupies a unique position in peptide bioregulation as the smallest molecule demonstrated to exert tissue-specific gene-regulatory effects in the Khavinson framework. The dipeptide was identified through systematic study of thymic peptide extracts, where researchers isolated the minimal amino acid sequence capable of reproducing the immunomodulatory effects of the full thymic extract thymalin. The resulting KE dipeptide retained the ability to stimulate T-lymphocyte differentiation, modulate CD4+/CD8+ T-cell ratios, and influence the production of key cytokines including interleukin-2 (IL-2) and interferon-gamma (IFN-γ).

The peptide's biological activity is proposed to arise not through classical receptor-ligand pharmacology but through direct binding to DNA in the minor groove of the double helix at specific promoter regions. This epigenetic mechanism — unusual for a molecule of this size — has been supported by molecular modeling studies and chromatin reactivation experiments in lymphocytes from elderly subjects. Vilon's capacity to reverse age-related heterochromatin condensation and restore immune gene expression toward youthful patterns underlies its classification as a geroprotective agent.

A particularly significant property of Vilon is its oral bioavailability. Most peptide therapeutics require parenteral administration due to rapid degradation by gastrointestinal proteases. However, dipeptides occupy a privileged position: they are substrates for the PepT1 (SLC15A1) intestinal peptide transporter, which actively transports di- and tripeptides across the intestinal epithelium. Furthermore, the KE sequence has minimal susceptibility to the major intestinal endopeptidases (trypsin, chymotrypsin, pepsin), which require longer peptide chains for efficient catalysis. This combination of active transport and protease resistance makes Vilon one of the few bioregulatory peptides that can be administered orally.

Mechanism of Action

Vilon operates through multiple interconnected mechanisms consistent with the Khavinson bioregulatory peptide framework, in which short peptides modulate gene expression through direct DNA interactions rather than classical receptor-ligand pharmacology.

Thymulin-Like Activity

Vilon mimics the biological effects of thymulin (facteur thymique sérique, FTS), the zinc-dependent nonapeptide hormone produced by thymic epithelial cells. Thymulin is the only thymic hormone with a fully characterized amino acid sequence (Glu-Ala-Lys-Ser-Gln-Gly-Gly-Ser-Asn, requiring zinc for biological activity) and is essential for T-cell maturation and differentiation within the thymus. Serum thymulin levels decline progressively with age-related thymic involution, reaching near-undetectable levels by age 60. Khavinson & Morozov (2003) demonstrated that Vilon's thymulin-like activity promotes T-lymphocyte differentiation and functional maturation in aging immune systems, effectively compensating for the loss of endogenous thymic peptide signaling.

Peptide-DNA Interaction and Epigenetic Regulation

Khavinson et al. (2005) described the molecular model by which short peptides including Vilon interact with specific DNA sequences in gene promoter regions. The KE dipeptide binds to the minor groove of double-stranded DNA through a combination of electrostatic interactions (lysine ε-amino group with phosphate backbone, glutamate carboxylate with nucleotide bases) and hydrogen bonding. This binding modulates transcription of genes involved in immune function, cell proliferation, and differentiation. The interaction model explains how a dipeptide can exert specific biological effects despite lacking a traditional receptor-binding pharmacology — the peptide acts as a direct transcriptional modulator at the genomic level.

CD4/CD8 Ratio Modulation

Vilon influences the balance between CD4+ helper T cells and CD8+ cytotoxic T cells, a ratio that is critically dysregulated in aging and immunosenescence. In aged subjects, the CD4/CD8 ratio typically shifts due to clonal expansion of memory CD8+ T cells and declining naive T-cell output from the involuted thymus. Khavinson (2002) demonstrated that Vilon treatment partially normalizes CD4/CD8 ratios in elderly subjects by promoting thymic-dependent T-cell differentiation pathways, restoring a more balanced immunological profile.

Cytokine Regulation

Vilon modulates production of key immune cytokines, particularly IL-2 and IFN-γ. Khavinson et al. (2003) demonstrated that the peptide influences cytokine gene expression at the promoter level, promoting a Th1-biased immune response characterized by enhanced cellular immunity. IL-2 production drives T-cell proliferation and differentiation, while IFN-γ activates macrophages and enhances MHC class I and II expression. By upregulating these cytokines, Vilon promotes the effector functions required for immune surveillance against virally infected and malignant cells.

Chromatin Remodeling

Consistent with other Khavinson bioregulators, Vilon induces decondensation of heterochromatin in lymphocytes from elderly subjects, reactivating genes silenced by age-related chromatin condensation. Lezhava et al. (2006) showed that Vilon treatment of peripheral blood lymphocytes from donors aged 76-80 years produced measurable decondensation of constitutive heterochromatin (chromosome regions 1, 9, and 16). This chromatin-level effect is proposed as the upstream mechanism through which the dipeptide restores immune gene expression toward youthful patterns. Despite its minimal size (just two amino acids), Vilon produced chromatin changes comparable to those induced by larger bioregulatory peptides including Epithalon and Livagen.

The chromatin remodeling mechanism provides an explanation for several otherwise puzzling aspects of Vilon's pharmacology:

• Duration of effect exceeding peptide half-life: Vilon's plasma half-life is minutes, but its biological effects persist for weeks to months. Chromatin modifications (histone acetylation/methylation changes, nucleosome repositioning) are maintained by cellular epigenetic machinery long after the initiating signal is removed.
• Course-based dosing: The cyclical administration protocol (10-30 day courses with months between courses) is consistent with an epigenetic mechanism where brief peptide exposure triggers sustained chromatin changes.
• Tissue specificity without receptor selectivity: Different cell types maintain different chromatin landscapes. The same KE dipeptide encounters different accessible promoter regions in different tissues, explaining tissue-specific effects without requiring tissue-specific receptors.

Immune Cell Proliferation and Differentiation

Vilon stimulates proliferation and functional activity of T-lymphocyte populations through multiple mechanisms. In aged animal models and elderly human subjects, the dipeptide increases absolute numbers and functional capacity of both CD4+ and CD8+ T cells (Khavinson, 2002). The peptide promotes transition from naive to effector T-cell phenotypes, enhances T-cell receptor (TCR) signaling competence, and supports the generation of functional immunological memory — all processes that decline with immunosenescence.

Safety Profile

Vilon has an excellent safety profile across decades of Russian clinical and research use, with no significant adverse effects reported in multiple studies and clinical applications. The dipeptide's favorable safety characteristics derive from several intrinsic properties:

• Minimal immunogenicity: Dipeptides are far too small to elicit antibody responses or T-cell-mediated immune reactions. The minimum size for immunogenicity is typically 8-10 amino acids for MHC class I presentation.
• Natural amino acid composition: Vilon is composed exclusively of two proteinogenic amino acids (L-lysine and L-glutamic acid) that are present in normal dietary protein and participate in standard metabolic pathways.
• Rapid clearance: The dipeptide is rapidly degraded to its constituent amino acids by ubiquitous serum peptidases, preventing accumulation.
• No known drug interactions: The gene-expression-level mechanism is distinct from conventional pharmacological targets, and no clinically significant drug interactions have been reported.
• Elderly population safety: The primary target demographic for Vilon is elderly individuals with immunosenescence. The 15-year observational study by Khavinson & Morozov (2003) included long-term safety follow-up in patients aged 60-74+ years with no concerning safety signals.
• No oncogenic risk: Despite modulating immune cell proliferation, Vilon has not been associated with increased tumor incidence in any published study. Its mechanism of action promotes immune surveillance against tumors rather than uncontrolled cell proliferation.

Limitations: As with other Khavinson bioregulators, no controlled safety studies meeting international regulatory standards (ICH guidelines) have been published. Long-term safety in Western clinical trial frameworks remains to be established. Pregnancy and lactation safety data are not available. Gene-expression-modulating agents should be used with caution during pregnancy and lactation due to theoretical concerns about effects on fetal or neonatal immune development.

Theoretical safety considerations:

• Excessive immune stimulation: In patients with autoimmune conditions, Th1-promoting effects (IFN-γ, IL-2 upregulation) could theoretically exacerbate autoimmune pathology. Vilon has not been specifically studied in autoimmune populations, and caution is warranted.
• Cytokine storm risk: While Vilon promotes balanced cytokine modulation rather than massive cytokine release, use during active severe infections (where cytokine storm is a risk) should be approached cautiously.
• Interaction with immunosuppressive therapy: Patients on calcineurin inhibitors (cyclosporine, tacrolimus), mTOR inhibitors (sirolimus), or anti-proliferative agents (mycophenolate) should exercise caution, as Vilon's immunostimulatory effects could theoretically antagonize immunosuppression in transplant recipients.

Pharmacokinetic Profile